Use of biguanides and the risk of colorectal cancer: A register-based cohort study

Current Drug Safety

Volumn 8, Issue 5, 2013, Pages 349-356

  Knapen, Lotte M ^a,b   Dittrich, Suzanne T A M ^a,b   de Vries, Frank ^a,b,c,d   Starup Linde, Jakob ^e,f   Vestergaard, Peter ^f,g   Henry, Ronald M A ^a   Stolk, Leo M L ^a,b   Neef, Cees ^a,b   Bazelier, Marloes T ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biguanide; Colorectal neoplasms; Diabetes mellitus type two (T2DM); Malignancies; Metformin; Pharmacoepidemiology

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PHENFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIGUANIDES; COHORT STUDIES; COLORECTAL NEOPLASMS; COMORBIDITY; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; PHENFORMIN; POPULATION; REGISTRIES; RISK FACTORS; YOUNG ADULT;

EID: 84891540896     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15680266113136660068     Document Type: Article

References (41)

1. Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011; 18(2): 117-52.
2. Wild S, Goglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
3. Wulffelé MG, Kooy A, Zeeuw D de, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes: a systematic review. J Intern Med 2004; 256; 1-14.
4. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and metaanalysis. PLoS One 2012; 7(3): e33411.
5. Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9(33).
6. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310(5754): 1642-6.
7. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabes: a metaanalysis. Oncologist 2012; 17(6): 813-22.
8. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care 2011; 34; 2323-8.
9. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011; 26(11): 863-76.
10. Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer 2012; 48(9): 1269-82.
11. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Nat Cancer Institute 2005; 97(22): 1679-87.
12. Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: A meta-analysis of twenty four cohort studies. Colorectal Dis 2012; 14(11): 1307-12.
13. Yang YX, Hennesy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127; 1044-50.
14. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2012; 21(2): 280-6.
15. Currie CJ, Poole CD, Gale EAM. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52(9): 1766-77.
16. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-20.
17. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Danish Med Bull 1999; 46(3): 263-8.
18. Helqvist L, Erichsen R, Gammelager H, Johansen MB, Sørensen HT. Quality of ICD-10 colorectal cancer diagnosis codes in the Danish National Registry of Patients. Eur J Cancer Care 2012; 21(6): 722-7.
19. Hardie DG. AMP-activated protein kinase as a drug target. Ann Rev Pharmacol Toxicol 2007; 47: 185-210.
20. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. New Engl J Med 2005; 352(21): 2184-92.
21. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010; 59: 1572-85.
22. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.
23. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323(18): 1228-33.
24. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138(6): 2044-58.
25. Rothwell PM, Price JF, Fowkes GR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
26. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53(9): 1838-45.
27. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and allcause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55: 2593-603.
28. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
29. Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf 2012; 21(7): 770-4.
30. De Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the general practice research database. Intern J Epidemiol 2006; 35(5): 1301-8.
31. De Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Intern 2011; 22(5): 1641-2.
32. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9): 1620-5.
33. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Nat Cancer Instit 2005; 97(22): 1679-87.
34. Giovannucci E, Harlan D, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
35. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
36. Roumie CL, Liu X, Choma NN, et al. Initiation of sulphonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf 2012; 21(5): 515-23.
37. Huizinga MM, Roumie CL, Greevy RA, et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Pharmacoepidemiol Drug Saf 2010; 19(11): 1108-12.
38. Rasool S, Kadla SA, Rasool V, Ganai BA. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumour Biol 2013; 34(5): 2469-76.
39. Ford ES, Malarcher AM, Herman WH, Aubert RE. Diabetes mellitus and cigarette smoking. Findings from the 1989 National Health Interview Survey. Diabetes Care 1994; 17(7): 688-92.
40. Joseph J, Svartberg J, Njølstad I, Schirmer H. Incidence of and risk factors for type-2 diabetes in a general population: the Tromsø Study. Scand J Pub Health 2010; 38(7): 768-75.
41. Wolkin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Brit J Cancer 2009; 100(4): 611-6.